Investments, Funding & Disinvestment

The Kingdom’s digital health market is projected to reach US$11.07 billion by 2033, highlighting growing demand for advanced healthcare technologies.

The transaction will be completed through a share purchase agreement with SEVER Life Sciences, under which Alfasigma will acquire 100% of Nordic Group and its subsidiaries.

Named after King Nyabela of the Ndzundza-Ndebele people, the 220-bed district hospital will provide essential healthcare services to more than 240,000 residents of the Steve Tshwete Local Municipality.

Under the revised agreement, Exor can raise its shareholding in Philips to up to 22% of the company’s issued ordinary share capital and voting rights, compared with the previous 20% limit.

The investment forms part of BMS’ broader US$ 40 billion commitment to strengthening its US operations, including its manufacturing and research and development (R&D) capabilities.

As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.

The AI-powered guidance will focus on building sustainable habits related to diet, physical activity, recovery and sleep, helping individuals make informed lifestyle decisions in real time.

The approval allows the company’s PGDx elio tissue complete CDx to be used in hospitals and clinical laboratories across the United States to help identify patients who may benefit from targeted treatment.

The agreement covers joint clinical studies that will combine BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors developed by Revolution Medicines: daraxonrasib, zoldonrasib, elironrasib and RMC-5127.

The study is designed to provide confirmatory evidence for lacutamab in two CTCL subtypes, Sézary syndrome and mycosis fungoides, potentially supporting full regulatory approval.